These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 30604197)
1. International multicenter randomized, placebo-controlled phase III clinical trial of β-D-mannuronic acid in rheumatoid arthritis patients. Rezaieyazdi Z; Farooqi A; Soleymani-Salehabadi H; Ahmadzadeh A; Aslani M; Omidian S; Sadoughi A; Vahidi Z; Khodashahi M; Zamurrad S; Mortazavi-Jahromi SS; Fallahzadeh H; Hosseini M; Aghazadeh Z; Ekhtiari P; Matsuo H; Rehm BHA; Cuzzocrea S; D'Aniello A; Mirshafiey A Inflammopharmacology; 2019 Oct; 27(5):911-921. PubMed ID: 30604197 [TBL] [Abstract][Full Text] [Related]
2. A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of β-D-mannuronic acid in rheumatoid arthritis patients. Ahmadi H; Jamshidi AR; Gharibdoost F; Mahmoudi M; Rastkari N; Mostafaei S; Fattahi MJ; Vojdanian M; Cuzzocrea S; Rehm BHA; Matsuo H; Hosseini M; Aghazadeh Z; Mortazavi-Jahromi SS; Mirshafiey A Inflammopharmacology; 2018 Jun; 26(3):737-745. PubMed ID: 29696564 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial. Fattahi MJ; Jamshidi AR; Mahmoudi M; Vojdanian M; Yekaninejad MS; Jafarnezhad-Ansariha F; Ahmadi H; Rehm BHA; Matsuo H; Cuzzocrea S; Hosseini M; Hashemi SN; Aghazadeh Z; Mirshafiey A Int Immunopharmacol; 2018 Jan; 54():112-117. PubMed ID: 29127910 [TBL] [Abstract][Full Text] [Related]
4. The Oral Administration Effect of Drug Mannuronic Acid (M2000) on Gene Expression of Matrix and Tissue Inhibitor of Metalloproteinases in Rheumatoid Arthritis Patients. Gaafar NAG; Aslani M; Aghazadeh Z; Razavi A; Mirshafiey A Curr Drug Discov Technol; 2020; 17(5):704-710. PubMed ID: 31250758 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362 [TBL] [Abstract][Full Text] [Related]
6. Targeting of circulating Th17 cells by β-D-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis. Ahmadi H; Mahmoudi M; Gharibdoost F; Vojdanian M; Jamshidi AR; Fattahi MJ; Aghazadeh Z; Barati A; Mirshafiey A Inflammopharmacology; 2018 Feb; 26(1):57-65. PubMed ID: 29063487 [TBL] [Abstract][Full Text] [Related]
7. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.]. Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321 [TBL] [Abstract][Full Text] [Related]
8. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU; Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670 [TBL] [Abstract][Full Text] [Related]
10. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study. Blanco FJ; Möricke R; Dokoupilova E; Codding C; Neal J; Andersson M; Rohrer S; Richards H Arthritis Rheumatol; 2017 Jun; 69(6):1144-1153. PubMed ID: 28217871 [TBL] [Abstract][Full Text] [Related]
11. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC; Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627 [TBL] [Abstract][Full Text] [Related]
12. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617 [TBL] [Abstract][Full Text] [Related]
14. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial]. Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361 [TBL] [Abstract][Full Text] [Related]
15. The Anti-Migraine Effects of M2000 (β-D-Mannuronic Acid) on a Patient with Rheumatoid Arthritis: Case Report. Vojdanian M; Ahmadi H; Jamshidi AR; Mahmoudi M; Gharibdoost F; Barati A; Mirshafiey A Curr Clin Pharmacol; 2017; 12(2):127-130. PubMed ID: 28578645 [TBL] [Abstract][Full Text] [Related]
16. The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients. Aslani M; Ahmadzadeh A; Rezaieyazdi Z; Mortazavi-Jahromi SS; Barati A; Hosseini M; Mirshafiey A Recent Pat Inflamm Allergy Drug Discov; 2020; 14(1):69-77. PubMed ID: 31729947 [TBL] [Abstract][Full Text] [Related]
17. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). Kennedy WP; Simon JA; Offutt C; Horn P; Herman A; Townsend MJ; Tang MT; Grogan JL; Hsieh F; Davis JC Arthritis Res Ther; 2014 Oct; 16(5):467. PubMed ID: 25359150 [TBL] [Abstract][Full Text] [Related]
19. Hematological Improvement of Patients with Active Rheumatoid Arthritis by β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property. Ahmadi H; Jamshidi AR; Mahmoudi M; Gharibdoost F; Vojdanian M; Fattahi MJ; Rastkari N; Aghazadeh Z; Mirshafiey A Iran J Allergy Asthma Immunol; 2017 Oct; 16(5):433-442. PubMed ID: 29149783 [TBL] [Abstract][Full Text] [Related]
20. The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis. Ahmadi H; Jamshidi AR; Mahmoudi M; Cuzzocrea S; Fattahi MJ; Barati A; Rehm BHA; Matsuo H; Mirshafiey A Curr Drug Discov Technol; 2017; 14(3):206-214. PubMed ID: 28325148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]